Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5424200 | 0.81 | SLC6A2 (0.36) | RAB9AHPGDNPC1GAAFFAR4 | |
| SCHEMBL4413276 | 0.80 | CYP4F2 (0.37) | RAB9AHPGDFFAR4ALDH1A1KMT2A | |
| SCHEMBL2293511 | 0.80 | ALDH1A1 (0.33) | RAB9AFFAR4ALDH1A1KMT2A | |
| SCHEMBL5411792 | 0.79 | IDO1 (0.40) | HPGDIDO1 | |
| SCHEMBL4757401 | 0.79 | IDO1 (0.50) | LMNARAB9AHPGDNPC1GAA | |
| SCHEMBL2599655 | 0.79 | ALDH1A1 (0.35) | RAB9AHPGDGAAFFAR4ALDH1A1 | |
| SCHEMBL31377067 | 0.79 | FFAR4 (0.32) | RAB9AFFAR4ALDH1A1KMT2ATHRB | |
| SCHEMBL2761376 | 0.79 | ALDH1A1 (0.35) | RAB9AFFAR4ALDH1A1KMT2AHTT | |
| SCHEMBL29800004 | 0.79 | ALDH1A1 (0.35) | RAB9AFFAR4ALDH1A1KMT2AHTT | |
| SCHEMBL500206 | 0.79 | FFAR4 (0.32) | FFAR4PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044232-A1 | Production methods of citalopram and intermediates therefor | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| US-20020151728-A1 | Production methods of 5-phthalancarbonitrile compound and an intermediate therefor | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2002-10-17 | — | — | US | disclosed |
| US-20010056194-A1 | Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056194-A1 | Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate | SLC39A11, CYP4F11, SLC39A14 | LMNA 3508/4885RAB9A 3171/4885HPGD 1959/4885 |
| US-20020151728-A1 | Production methods of 5-phthalancarbonitrile compound and an intermediate therefor | SLC39A11, CYP4F11, SLC39A14 | LMNA 4006/4885RAB9A 3178/4885HPGD 1976/4885 |
| US-20040044232-A1 | Production methods of citalopram and intermediates therefor | PPIF, SLC39A11, CYP4F11 | LMNA 2954/4885RAB9A 3861/4885HPGD 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.